Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   36079   clinical trials with a EudraCT protocol, of which   5931   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2016-002880-33
    Sponsor's Protocol Code Number:PINDEX
    National Competent Authority:Finland - Fimea
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2016-10-17
    Trial results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFinland - Fimea
    A.2EudraCT number2016-002880-33
    A.3Full title of the trial
    Bioavailability and pharmacokinetics of intranasal dexmedetomidine in children
    Nenän limakalvolle annostellun deksmedetomidiinin farmakokinetiikka lapsipotilailla ja imeväisillä
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Pharmacological characteristics of intranasally given dexmedetomidine
    in paediatric patients
    Nenän limakalvolle annostellun deksmedetomidiinin kulkeutuminen elimistössä lapsipotilailla.
    A.4.1Sponsor's protocol code numberPINDEX
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorUniversity of Turku
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportTurku University Hospital
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationTurku University Hospital
    B.5.2Functional name of contact pointTurku Clinical Research Centre
    B.5.3 Address:
    B.5.3.1Street AddressKiinamyllynkatu 4-8
    B.5.3.2Town/ cityTurku
    B.5.3.3Post code20100
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D. name Dexdor
    D. of the Marketing Authorisation holderOrion Corporation
    D.2.1.2Country which granted the Marketing AuthorisationFinland
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntranasal use (Noncurrent)
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 113775-47-6
    D.3.9.4EV Substance CodeSUB07037MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg/ml microgram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Paediatric patients scheduled for minor procedures such as intra-articular drug injections, hernia repair, bronchoscopy or magnetic resonance imaging.
    Lapsipotilaat jotka tulevat pieneen yleisanestesiaa vaativaan toimenpiteeseen, kuten intra-artikulaarinen lääkeinjektio, hernioplastia, bronkoskopia tai MRI-kuvaus
    E.1.1.1Medical condition in easily understood language
    Paediatric patients scheduled for minor procedures such as drug injection in to the joints, hernia repair, bronchoscopy or magnetic resonance imaging
    Lapsipotilaat jotka tulevat pieneen yleisanestesiaa vaativaan toimenpiteeseen, kuten nivelen sisäinen lääkkeenanto, tyräkorjaus, keuhkojen tähystys tai magneettikuvaus.
    E.1.1.2Therapeutic area Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    We aim to characterize the pharmacokinetics of dexmedetomidine after intranasal dosing.
    Deksmedetomidiinin farmakokinetiikan karakterisointi nenään annostellun lääkeannoksen jälkeen.
    E.2.2Secondary objectives of the trial
    We will also monitor the haemodynamic effects, local and systemic safety and local tolerability of intranasally administered dexmedetomidine
    Deksmedetomidiinin verenkiertovaikutukset, paikallinen ja systeeminen turvalliusuus ja paikallinen siedettävyys nenäannostelun jälkeen.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. The child is scheduled for intra-articular drug injections, hernia repair, bronchoscopy or another similar minor procedure or magnetic resonance imaging requiring sedation or anesthesia
    2. Guardians and patients (if relevant) with fluent skills in the Finnish or Swedish language (to understand the given information, to be able to give informed consent and communicate with the study personnel).
    3. Age between 1 month and 12 years.
    4. Normal developmental status including growth (SD -1.5-1.5)
    5. Written informed consent from the guardian and the patient (when relevant).
    1. Potilaalle on ohjelmoitu sedaatiota tai yleisanestesiaa vaativa intra-artikulaarinen lääkeinjektio, hernioplastia, bronkoskopia tai vastaava pieni toimenpide tai magneettikuvaus.
    E.4Principal exclusion criteria
    1 A previous history of intolerance to the study drug or to related compounds and additives
    2. Prior drug therapy with dexmedetomidine in the 14 days prior to the study.
    3. Use of any drugs known to cause enzyme induction or inhibition for a period of 30 days prior to the study, use of any natural products (including grapefruit products) for at least 14 days prior to the study and caffeine containing products for at least 24 hours prior to the study. The use of regular doses of paracetamol is allowed.
    4. Existing or recent significant disease that could influence the study outcome or cause a health hazard for the subject if he/she would participate in the study.
    5. Participation in any other clinical study involving investigational or marketed drug products concomitantly or within one month prior to the entry into this study.
    6. Clinically significant abnormal findings in physical examination or laboratory screening [routine haematology (haemoglobin, haematocrit, red blood cell count, white blood cell count, platelets), renal function tests (creatinine, urea) and liver function tests (bilirubin)].
    1. Yliherkkyys tutkimuksessa käytettävälle lääkkeelle tai sen apuaineille.
    2. Deksmedetomidiinilla toteutettu lääkehoito 14 päivää ennen tutkimusta.
    3. Deksmedetomidiinin aineenvaihduntaan vaikuttavan lääkeaineen/-aineiden käyttö tutkimusta edeltävän kuukauden aikana.
    4. Aikaisempi lääkeaineiden imeytymiseen, jakautumiseen, aineenvaihduntaan ja/tai eritykseen vaikuttava sairaus
    5. Osallistuminen muuhun lääketutkimukseen alle kuukautta edeltävällä ajalla tästä tutkimuksesta.
    6. Kliinisesti merkittävät poikkeavuudet lääkärin tutkimuksessa, EKG:ssa tai laboratorioarvoissa
    E.5 End points
    E.5.1Primary end point(s)
    The bioavailability of intranasally given dexmedetomidine in children as characterized against previously available intravenous study data
    Nenään annostellun deksmedetomidiinin hyötyosuus lapsilla, verrattuna aikaisempaan laskimonsisäisesti toteutettuun annosteluun.
    E.5.1.1Timepoint(s) of evaluation of this end point
    24 h after administration
    24 tuntia annostelun jälkeen
    E.5.2Secondary end point(s)
    The pharmacokinetics and –dynamics of intranasally given dexmedetomidine in children.
    Nenään annostellun deksmedetomidiinin farmakokinetiikka ja -dynamiikka lapsilla.
    E.5.2.1Timepoint(s) of evaluation of this end point
    24 h after administration
    24 tuntia annostelun jälkeen
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety No
    E.6.5Efficacy No
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Viimeinen tutkimuskäynti suoritettu.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 50
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F. of subjects for this age range: 50
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F. of subjects incapable of giving consent
    Children (2-6 years old)
    F.3.3.7Others Yes
    F. of other specific vulnerable populations
    F.4 Planned number of subjects to be included
    F.4.1In the member state50
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Ei ole
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-10-28
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-09-20
    P. End of Trial
    P.End of Trial StatusOngoing
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2019 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice